Evidence and desperation in off-label prescribing: Recombinant factor VIIa

BMJ (Online)

Volumn 344, Issue 7840, 2012, Pages

  Lipworth, Wendy ^a,b   Kerridge, Ian ^b   Little, Miles ^b   Day, Richard ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

BLEEDING; BRAIN HEMORRHAGE; CLINICAL PRACTICE; CULTURAL FACTOR; DRUG INDICATION; EVIDENCE BASED MEDICINE; HEMOPHILIA; HUMAN; MEDICOLEGAL ASPECT; MORALITY; MORTALITY; OFF LABEL DRUG USE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; REVIEW;

COAGULANTS; DRUG COSTS; EVIDENCE-BASED MEDICINE; FACTOR VIIA; HEMORRHAGE; HUMANS; OFF-LABEL USE;

EID: 84859009034     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d7926     Document Type: Review

References (20)

1. Bright JL. Positive outcomes through the appropriate use of off-label prescribing. Arch Intern Med 2006;166:2554-5. (Pubitemid 44913245)
2. Largent EA, Miller FG, Pearson SD. Going off-label without venturing off-course. Evidence and ethical off-label prescribing. Arch Intern Med 2009;169:1745-7.
3. Logan AC, Yank V, Stafford RS. Off-label use of recombinant factor VII in US hospitals: analysis of hospital records. Ann Intern Med 2011;154:516-22.
4. Dutton RP, Parr M, Tortella BJ, Champion HR, Bernard GR, Boffard K, et al. Recombinant activated factor VII safety in trauma patients: results from the CONTROL trial. J Trauma 2011;71:12-8.
5. Kalina M, Tinkoff G, Fulda G. Massive postpartum hemorrhage: recombinant factor VIIa use is safe but not effective. Del Med J 2011;83:109-13.
6. Witmer CM, Huang Y-S, Lynch K, Raffini LJ, Shah SS. Off-label recombinant factor VIIa use and thrombosis in children: a multi-center cohort study. J Pediatr 2011;158:820-5.e1.
7. Yank V, Tuohy CV, Logan AC, Bravata DM, Staudenmayer K, Eisenhut R, et al. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med 2011:529-40.
8. Lin Y, Stanworth S, Birchall J, Doree C, Hyde C. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev 2011:CD005011.
9. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010;363:1791-800.
10. Avorn J, Kesselheim A. A hemorrhage of off-label use. Ann Intern Med 2011;154:566-67.
11. Yank V, Tuohy CV, Logan AC, Bravata DM, Staudenmayer K, Eisenhut R, et al. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Inter Med 2011;154:529-40.
12. Karkouti K, Levy J. A hemorrhage of off-label use [letter]. Ann Intern Med 2011;155:339.
13. Jonsen A. Bentham in a box: technology assessment and health care allocation. Law Med Health Care 1986;14:172-4.
14. McKie J, Richardson J. The rule of rescue. Soc Sci Med 2003;56:2407-19. (Pubitemid 36555359)
15. Hadorn DC. Setting health-care priorities in Oregon-cost-effectiveness meets the rule of rescue. JAMA 1991;265:2218-25.
16. Marks I. Blood-injury phobia: a review. Am J Psychiatry 1988;145:1207-13.
17. Gilovich T, Medvec VH, Kahneman D. Varieties of regret: A debate and partial resolution. Psychol Rev 1998;105:602-5.
18. Kesselheim AS, Mello MM, Studdert DM. Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints. PLoS Med 2011;8:e1000431.
19. Ray C. Novo Nordisk to settle marketing suit. Wall Street Journal 2011, 10 June.
20. Stiell IG, Hebert PC, Weitzman BN, Wells GA, Raman S, Stark RM, et al. High-dose epinephrine in adult cardiac arrest. N Engl J Med 1992;327:1045-50.